Published in final edited form as:

J Steroid Biochem Mol Biol. 2010 July ; 121(1-2): 193–198. doi:10.1016/j.jsbmb.2010.03.064.

VITAMIN D INHIBITION OF TACE AND PREVENTION OF RENAL OSTEODYSTROPHY AND CARDIOVASCULAR MORTALITY

Adriana Dusso^{*}, Maria Vittoria Arcidiacono, Jing Yang, and Masanori Tokumoto

Renal Division, Washington University School of Medicine, St. Louis, Missouri, USA 63110

Abstract

In the course of kidney disease, the progressive loss of renal capacity to maintain normal serum levels of 1,25-dihydroxyvitamin D (1,25(OH)₂D) is a main contributor to parathyroid hyperplasia and high serum PTH. High PTH causes mineral and skeletal abnormalities predisposing to ectopic calcifications and increased mortality. Intriguingly, replacement therapy with 1,25(OH)₂D or its less calcemic analogs was recently shown to improve survival in kidney disease patients through renal and cardiovascular protective actions that are independent of PTH suppression. This work presents preliminary evidence that 1,25(OH)₂D inhibition of TACE (Tumor necrosis factor Alpha Converting Enzyme) is a potential common mechanism underlying the efficacy of therapy with 1,25(OH)₂D or its analogs to improve outcomes in chronic kidney disease. 1,25(OH)₂D prevents/moderates not only the onset and progression of parathyroid TACE/TGF α -driven secondary hyperparathyroidism, but, more significantly, renal TACE/TGF α -driven fibrotic and inflammatory lesions to the renal parenchyma, and TACE/TNF α -driven systemic inflammation, which is known to aggravate renal and cardiovascular lesions and enhance the risk of vascular calcification and cardiovascular mortality.

Keywords

ADAM17; kidney disease; secondary hyperparathyroidism; renoprotection

INTRODUCTION

In chronic kidney disease (CKD), disturbances in mineral and bone metabolism are prevalent, and an important cause of morbidity, decreased quality of life, and extraskeletal calcifications that have been associated with increased cardiovascular mortality [1]. The progressive loss of renal capacity to maintain normal serum levels of 1,25-dihydroxyvitamin D (1,25(OH)₂D), the hormonal form of vitamin D, is a main contributor to the development of secondary hyperparathyroidism (SH). This disorder is characterized by parathyroid hyperplasia and high serum PTH. The elevations in serum PTH cause mineral and skeletal abnormalities predisposing to renal and cardiovascular damage, ectopic calcifications, and increased mortality. Because 1,25(OH)₂D suppresses parathyroid cell growth and PTH gene transcription, treatment with 1,25(OH)₂D or its less calcemic analogs has been the therapy

^{*}Corresponding author: Adriana Dusso, Ph. D., Research Associate Professor of Medicine, Renal Division, Box 8126, Department of Internal Medicine, 660 S. Euclid Ave., St. Louis, MO 63110, Phone: (314) 362-8243, FAX: (314) 362-8237, adusso@DOM.wustl.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

of choice for SH for the last 25 years [1]. At present, the importance of correcting the abnormalities in vitamin D metabolism in CKD is being investigated vigorously in view of observational studies in hemodialysis patients suggesting a potential survival benefit of 1,25(OH)₂D replacement therapy. Intriguingly, the improved outcomes upon treatment with active vitamin D metabolites (1,25(OH)₂D or its less calcemic analogs) involve renal and cardiovascular protective actions that are unrelated to their efficacy to suppress PTH [2]. Thus, a major challenge for nephrologists is the identification of the mechanisms underlying 1,25(OH)₂D efficacy to improve outcomes in CKD patients in a PTH-independent manner. This review presents preliminary evidence of 1,25(OH)₂D inhibition of TACE (Tumor necrosis factor- α converting enzyme, also known as ADAM17) as a potential mediator of 1,25(OH)₂D pro-survival properties in experimental CKD.

Increases in parathyroid TACE contribute to the onset and progression of SH

In advanced kidney disease, the severity of parathyroid hyperplasia determines not only a higher risk for cardiovascular mortality, but also a reduction in parathyroid levels of the vitamin D receptor (VDR) that makes these patients refractory to therapy with 1,25(OH)₂D or its analogs [1]. Our laboratory has identified the molecular link between the severity of parathyroid growth and VDR reduction: In rat and human SH, enhanced parathyroid expression of the potent growth promoter transforming growth factor- α (TGF α) and TGF α self-induction are sufficient to generate a feed-forward loop for TGF α activation of its receptor, the EGFR, which aggravates growth and reduces VDR [3,4]. In fact, halting this loop with the use of highly specific EGFR-tyrosine kinase inhibitors not only prevents further increases in parathyroid TGF α levels and growth rates, but also prevents VDR reduction, hence restoring the response to vitamin D therapy. Thus, the identification of the molecule(s) that causes the initial increases in parathyroid TGF α and starts the vicious cycle for disease progression is critical to improve outcomes. To this end, we focused on TACE (ADAM17), a metalloproteinase essential for EGFR signaling, as it releases the mature isoforms of TGF α and several other EGFR-activating ligands thereby enhancing autocrine/paracrine EGFR activation [5,6]. Enhanced TACE expression associates directly with the severity of several TGF α -driven hyperproliferative disorders that range from the induction of renal cystogenesis in polycystic kidney disease [7] to tumor progression in breast, colon, hepatocellular, renal and skin cancer [8,9]. In spite of the efficacy of TACE inhibition in attenuating these severe hyperproliferative disorders, the regulation of TACE expression remains poorly characterized. Transcriptional [10] and, most commonly, post transcriptional regulation [11] determine TACE levels and activity, as summarized in Fig. 1. Briefly, upon TACE synthesis, the removal of a domain of TACE that inhibits its catalytic activity at the late Golgi compartment is a critical pre-requisite for TACE maturation as it progresses through the secretory pathway to the cell surface [12]. TACE location at the cell membrane is mandatory for its sheddase function, and its inhibition effectively impairs TACE activity [13]. Post-transcriptional mechanisms that increase TACE activity in EGFR-driven cancer include the induction of TACE protein stabilization by the activated-EGFR [11], and TACE phosphorylation by activated ERK- or fibroblast growth factor receptor, which enhances TACE progression along the secretory pathway to the plasma membrane [14]. From these reports and our demonstration of the key role of TGF α in the parathyroid hyperplasia of kidney disease, we examined whether elevations in parathyroid TACE contribute to the TGF α -driven vicious cycle of exacerbated growth and VDR reduction. Preliminary studies in the rat model of CKD have shown that high dietary phosphate (P), a well known inducer of parathyroid TGF α expression and growth rates, also enhances parathyroid TACE content in early and established SH (See figures 2 and 3). However, high dietary P may not affect parathyroid TACE expression directly, but induce its translocation to the cell surface for the release of TGF α required to initiate EGFR-driven parathyroid cell growth and TACE stabilization. In fact, the inhibition of TGF α /EGFR-signals with the administration of

Erlotinib, a potent and highly specific inhibitor of EGFR activation, markedly attenuates high P-induction of parathyroid TACE content in early (See Fig. 2) and established (See Fig. 4) rat SH. Similarly, the prevention of TACE translocation to the cell surface to release TGF α appears to mediate the attenuation of parathyroid gland growth by dietary P restriction within the first week after 5/6 nephrectomy (NX) (See Fig. 2), as well as the halting of further parathyroid gland enlargement observed with the switch from a high to a low P diet from week 2 to week 4 after 5/6 NX (Fig. 3).

More significantly, 1,25(OH) $_2$ D inhibition of parathyroid TACE contributes to suppress parathyroid cell growth. 1,25(OH) $_2$ D could downregulate TACE simply by inhibiting its stabilization by activated EGFR, as 1,25(OH) $_2$ D potently inhibits EGFR activation [15]. To test this possibility, we compared the relative potency of the combination of 1,25(OH) $_2$ D (4 ng thrice weekly) + Erlotinib (6 mg/kg bw daily) from week 2 to week 4 after 5/6 NX with that of either monotherapy to moderate the elevations in parathyroid TACE expression induced by high dietary P, in our rat model of established SH. Figure 4 shows the higher efficacy of the Erlotinib+1,25(OH) $_2$ D combination to reduce parathyroid TACE content and, consequently, TACE-driven parathyroid gland enlargement (not shown) compared to that of either Erlotinib or 1,25(OH) $_2$ D, which suggests that 1,25(OH) $_2$ D inhibits parathyroid TACE expression in an EGFR-independent manner. Computer analysis of the TACE gene promoter showed no vitamin D responsive elements and several C/EBP binding sites. Therefore, 1,25(OH) $_2$ D suppression of parathyroid TACE expression could involve either VDR binding at distal VDREs in the TACE gene, or 1,25(OH) $_2$ D induction of parathyroid C/EBP β expression, as shown in renal cells and macrophages [16,17], and C/EBP β transcriptional activity at the C/EBP binding sites of the TACE gene. In established rat SH, 1,25(OH) $_2$ D synergy with Erlotinib to suppress parathyroid TACE and, consequently, parathyroid cell growth, associated with a 2-fold increase in C/EBP β levels compared to rats receiving vehicle or either monotherapy ($p < 0.05$; data not shown). Also in A431 cells, a human epidermoid carcinoma cell line that mimics hyperplastic parathyroid cells in TGF α , TACE, and VDR expression, 1,25(OH) $_2$ D synergy with Erlotinib in inhibiting TACE expression and growth rates, also involves increases in C/EBP β levels and a 5-fold suppression of TACE promoter activity (not shown).

Importantly, at early stages of kidney disease, the adequate correction of vitamin D deficiency appears to suffice to overcome the resistance to 1,25(OH) $_2$ D suppression of increases in parathyroid TACE content and TACE-driven gland enlargement caused by reductions in parathyroid VDR content. In fact, in 5/6 NX rats of 250 g of body weight (10 ml blood volume), early administration (starting 1 week after 5/6NX for 3 weeks) of a combination of 800 ng 25-hydroxyvitamin D weekly plus 16 ng of paricalcitol, a less calcemic 1,25(OH) $_2$ D analog, thrice weekly was more effective than 25(OH)D alone to raise serum 25(OH)D levels above 35 ng/ml, a threshold required to suppress PTH at early stages of human CKD [18], and than paricalcitol alone to prevent the increases in parathyroid TACE (not shown) and gland growth (Vehicle: 757 ± 64 ug; $n=6$ vs. Vitamin D: 507 ± 63 ; $n=5$). Serum 1,25(OH) $_2$ D levels were similar in rats receiving paricalcitol alone or the combination. Therefore, the increases in serum 25(OH)D above 35 ng/ml can partially account for the higher potency of the combination in preventing parathyroid gland enlargement. Elevations in serum 25(OH)D could correct the defective paricalcitol activation of the VDR to suppress TACE either directly, through 25(OH)D binding and activation of parathyroid VDR, or indirectly, through the enhancement of parathyroid 1,25(OH) $_2$ D synthesis and autocrine/paracrine VDR activation. Taken together, these findings suggest that parathyroid TACE activation is a key determinant of TGF α -driven hyperplasia in kidney disease. Effective correction of the vitamin D and/or 1,25(OH) $_2$ D deficiency of early and advanced kidney disease, by preventing increases in parathyroid TACE, should impede the onset of SH and/or attenuate its progression. Paricalcitol

inhibition of proteinuria and, consequently, of the urinary loss of 25(OH)D bound to vitamin D binding protein, could contribute to the higher efficacy of the combination to raise serum 25(OH)D compared to exclusive 25(OH)D dosage.

Inhibition of renal TACE contributes to 1,25(OH)₂D renoprotection

1,25(OH)₂D inhibition of TACE expression and activity in parathyroid and A431 cells has provided a potential mechanism for the renoprotective actions of active vitamin D metabolites unrelated to the suppression of SH, as increases in renal TACE expression have been reported to cause TGF α -driven renal lesions upon nephron reduction, ischemia, or prolonged exposure to angiotensin II (Ang II) in mice [19]. As summarized in figure 5, Ang II binding to and activation of Ang II-receptor 1 (AT-R1) enhances TACE expression and activity to release mature TGF α from its transmembrane precursor. Soluble TGF α binds to and activates the EGFR [19] causing renal parenchymal lesions, including glomerulosclerosis, tubular atrophy and/or dilation with microcyst formation, mild interstitial fibrosis, and multifocal mononuclear cell infiltration accompanied by severe proteinuria. Consistent with a crucial role of TACE and its activation of the TGF α /EGFR pathway in angiotensin II-driven renal damage, mice that either lack TGF α or express an inactivated EGFR in renal tubular cells, or wild type mice receiving specific TACE inhibitors are protected from renal lesions during chronic Ang II infusion in spite of hypertension [19]. The same Ang II/TACE-driven mechanism is the cause of renal lesions upon nephron reduction [19], as they can be ameliorated using Ang II receptor 1 antagonists. Because EGFR activation is known to stabilize TACE protein [11], nephron reduction and elevations in Ang II generate a feed-forward cycle for progressive increases in renal TACE activity and TACE/EGFR-driven renal lesions, thereby impairing not only renal 1,25(OH)₂D production by proximal tubules, but also 1,25(OH)₂D/VDR renoprotection through TGF α /EGFR-driven reductions in renal VDR content. Figure 6 depicts a strong inverse association between high renal TACE and VDR reduction, as demonstrated in the parathyroid glands [4].

In humans, TACE is constitutively expressed in renal distal tubules and podocytes. Kidney disease induces de novo TACE expression in proximal tubules, peritubular capillaries and glomerular mesangium, and upregulates podocyte TACE content [20]. The increases in glomerular and interstitial TACE expression coincided with enhanced TGF α and associated directly with structural damage, including mesangial matrix expansion, focal glomerulosclerosis, glomerular and interstitial macrophage infiltration, interstitial fibrosis, and decreased renal function, as demonstrated by lower estimated GFR and higher serum creatinine [20]. The adverse effects of renal TACE-driven TGF α activation of the EGFR could also compromise graft survival. In mice, renal EGFR activation was identified as the main determinant of the accelerated progression of renal lesions upon prolonged renal ischemia, a model that mimics the arterial stenosis during transplantation, as kidney damage was markedly reduced in mice carrying a proximal tubule specific EGFR inactivation [21]. Active vitamin D therapy effectively suppresses the TGF α /EGFR-pathway in the parathyroid glands [22], and therefore, a similar inhibition of EGFR activation in the kidney could partially account for its renoprotective effects. In fact, in severe proteinuric rats (higher than 2 g of urinary protein per mmol creatinine), EGFR activation was shown to be an important mediator of the endothelial dysfunction that causes the decline in renal blood flow (RBF) during hypertension induced CKD [23]. The inhibition of EGFR activation with small molecule tyrosine kinase inhibitors could restore renal hemodynamics and microvascular hypertrophy, but failed to completely reverse the disease because it has little effect on inflammation [23]. It is unclear from these findings how treatment with TACE inhibitors could prevent macrophage infiltration and fibrosis upon nephron reduction or prolonged exposure to angiotensin II in mice. A likely explanation is that the induction of

renal TACE content will not only enhance the release of TGF α to activate the EGFR, but also, of two other TACE substrates from their transmembrane precursors that are potent pro-inflammatory and pro-fibrotic molecules: the soluble forms of intercellular adhesion molecule 1 (ICAM-1) [24] and vascular adhesion molecule 1 (VCAM1) [25,26]. In kidney disease, whereas elevated plasma levels of soluble ICAM1 and VCAM1 correlate indirectly with GFR, soluble VCAM1 correlates directly with fibrinogen expression [27]. Furthermore, elevated serum levels of soluble ICAM1 and VCAM1 molecules are more accurate than proteinuria as markers of endothelial dysfunction and in predicting mortality in renal transplant recipients [28]. The reported increases in renal TACE in human kidney disease also provide some mechanistic understanding for the higher risk of cardiovascular mortality in these patients. TACE also releases the soluble form of the potent inflammatory cytokine TNF α , a critical contributor to systemic inflammation, and a leading cause of renal and cardiovascular damage and arterial calcification [29]. More significantly, a higher risk for cardiovascular mortality occurs in normal individuals carrying a TACE polymorphism that elicits higher TNF α release [30].

Active vitamin D also inhibits the rennin-angiotensin system and TGF α /EGFR signaling, and consequently, angiotensin II-driven TACE activation, EGFR-driven renal lesions, and EGFR-driven TACE stabilization suggesting that TACE inhibition could partially contribute to the renal and cardioprotective actions of active vitamin D that are unrelated to PTH suppression. Unpublished observations in the rat model of kidney disease support that an early correction of vitamin D deficiency effectively moderates the elevations in renal and macrophage TACE content. The reduced renal and macrophage TACE content associated directly with the halting TACE-driven proteinuria (Arcidiacono MV et al, J.Am. Soc. Nephrol. 19:743A, 2008) and a 70% decrease in aortic calcium deposition (not shown). A similar inhibition of renal TACE by active vitamin D therapy could occur in humans, and consequently, the reductions in serum levels of the markers of TACE activation TGF α , TNF α , ICAM1 and VCAM1 could reflect the efficacy of a safe vitamin D intervention in attenuating TACE-driven renal and cardiovascular lesions.

In summary, our preliminary findings in the rat model of kidney disease constitute the first demonstration of the anti-TACE properties of vitamin D. They suggest that a defective inhibition of parathyroid, renal, and/or macrophage TACE, caused by the vitamin D and/or 1,25(OH) $_2$ D deficiency of CKD, could trigger the onset and progression of SH, renal lesions, and systemic inflammation that aggravate renal and cardiovascular damage and predispose to arterial calcifications. The confirmation of the accuracy of serum markers of TACE activity to reflect renal and cardiovascular lesions in experimental kidney disease should help monitor the efficacy of treatment with vitamin D and/or 1,25(OH) $_2$ D or its analogs to inhibit renal (and/or macrophage) TACE and to customize therapy in a PTH-independent manner to improve outcomes in transplant recipients and in CKD patients.

Acknowledgments

This work was supported by grants to AD from NIDDK DK062713, CEDAR (Center for D-Activation Research), and Abbott Pharmaceuticals.

References

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. *Kidney Int Suppl* 1999;73:S14–19. [PubMed: 10633458]
2. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R. Activated injectable vitamin d and hemodialysis survival: a historical cohort study. *J Am Soc Nephrol* 2005;16(4):1115–1125. [PubMed: 15728786]

3. Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS. A Critical Role for Enhanced-TGF{alpha} and EGFR Expression in the Initiation of Parathyroid Hyperplasia in Experimental Kidney Disease. *Am J Physiol Renal Physiol*. 2005
4. Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, Lu Y, Tominaga Y, Cannata-Andia J, Slatopolsky E, Dusso AS. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. *J Am Soc Nephrol* 2008;19(2):310–320. [PubMed: 18216322]
5. Hinkle CL, Sunnarborg SW, Loisel D, Parker CE, Stevenson M, Russell WE, Lee DC. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. *J Biol Chem* 2004;279(23):24179–24188. [PubMed: 15066986]
6. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. *J Mammary Gland Biol Neoplasia* 1997;2(2):97–107. [PubMed: 10882296]
7. Nemo R, Murcia N, Dell KM. Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease. *Pediatr Res* 2005;57(5 Pt 1):732–737. [PubMed: 15774823]
8. Kenny PA, Bissell MJ. Targeting TACE-dependent EGFR ligand shedding in breast cancer. *J Clin Invest* 2007;117(2):337–345. [PubMed: 17218988]
9. Franovic A, Robert I, Smith K, Kurban G, Pause A, Gunaratnam L, Lee S. Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17. *Cancer Res* 2006;66(16):8083–8090. [PubMed: 16912185]
10. Bzowska M, Jura N, Lassak A, Black RA, Bereta J. Tumour necrosis factor-alpha stimulates expression of TNF-alpha converting enzyme in endothelial cells. *Eur J Biochem* 2004;271(13):2808–2820. [PubMed: 15206946]
11. Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J. Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. *J Biol Chem* 2007;282(11):8325–8331. [PubMed: 17227756]
12. Borroto A, Ruiz-Paz S, de la Torre TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A, Blobel CP, Baselga J, Arribas J. Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. *J Biol Chem* 2003;278(28):25933–25939. [PubMed: 12714588]
13. Obeid D, Nguyen J, Lesavre P, Bauvois B. Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells. *Oncogene* 2007;26(1):102–110. [PubMed: 16799629]
14. Fan H, Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. *Embo J* 1999;18(24):6962–6972. [PubMed: 10601018]
15. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, Barbieri MA, Dusso A. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. *J Biol Chem* 2002;277(41):38965–38971. [PubMed: 12181310]
16. Dhawan P, Peng X, Sutton AL, MacDonald PN, Croniger CM, Trautwein C, Centrella M, McCarthy TL, Christakos S. Functional cooperation between CCAAT/enhancer-binding proteins and the vitamin D receptor in regulation of 25-hydroxyvitamin D3 24-hydroxylase. *Mol Cell Biol* 2005;25(1):472–487. [PubMed: 15601867]
17. Esteban L, Vidal M, Dusso A. 1alpha-Hydroxylase transactivation by gamma-interferon in murine macrophages requires enhanced C/EBPbeta expression and activation. *J Steroid Biochem Mol Biol* 2004;89–90(1–5):131–137.
18. Al-Badr W, Martin KJ. Vitamin D and Kidney Disease. *Clin J Am Soc Nephrol*. 2008
19. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. *Nat Med* 2005;11(8):867–874. [PubMed: 16041383]

20. Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, van Goor H. ADAM17 upregulation in human renal disease: A role in modulating TGF- α availability? *Am J Physiol Renal Physiol*. 2009
21. Terzi F, Burtin M, Hekmati M, Federici P, Grimber G, Briand P, Friedlander G. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulo-interstitial lesions after renal injury. *J Clin Invest* 2000;106(2):225–234. [PubMed: 10903338]
22. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso A. p21^{WAF1} and TGF α mediate the parathyroid growth arrest by vitamin D and high calcium. *Kidney International* 2001;60:2109–2117. [PubMed: 11737585]
23. Helle F, Jouzel C, Chadjichristos C, Placier S, Flamant M, Guerrot D, Francois H, Dussaule JC, Chatziantoniou C. Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. *Am J Physiol Renal Physiol* 2009;297(1):F191–199. [PubMed: 19420116]
24. Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D'Souza SE. Tumor necrosis factor- α -converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). *J Biol Chem* 2006;281(6):3157–3164. [PubMed: 16332693]
25. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor- α -converting enzyme (ADAM 17). *J Biol Chem* 2003;278(39):37459–37464. [PubMed: 12878595]
26. Qian Y, Li S, Ye S, Chen Y, Zhai Z, Chen K, Yang G. Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. *J Endocrinol Invest* 2008;31(12):1069–1074. [PubMed: 19246972]
27. Stinghen AE, Goncalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, Pecoits-Filho R. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. *Nephron Clin Pract* 2009;111(2):c117–126. [PubMed: 19147993]
28. van Ree RM, Oterdoom LH, de Vries AP, Homan van der Heide JJ, van Son WJ, Navis G, Gans RO, Bakker SJ. Circulating markers of endothelial dysfunction interact with proteinuria in predicting mortality in renal transplant recipients. *Transplantation* 2008;86(12):1713–1719. [PubMed: 19104410]
29. Al-Aly Z. Arterial calcification: a tumor necrosis factor- α mediated vascular Wnt-opathy. *Transl Res* 2008;151(5):233–239. [PubMed: 18433704]
30. Morange PE, Tregouet DA, Godefroy T, Saut N, Bickel C, Rupprecht HJ, Lackner K, Barbaux S, Poirier O, Peiretti F, Nalbone G, Juhan-Vague I, Blankenberg S, Tiret L. Polymorphisms of the tumor necrosis factor- α (TNF) and the TNF- α converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. *J Mol Med* 2008;86(10):1153–1161. [PubMed: 18600307]

Figure 1. Regulation of TACE expression and activity

Transcriptional and post transcriptional mechanisms regulate cytosolic TACE content, its activation, stabilization, and translocation to the cell surface for its sheddase activity (See text for details)

Figure 2. Dietary P intake regulates parathyroid TACE expression

Representative immunostaining of phosphorylated ERK1/2 (P-ERK1/2) and TACE, in parathyroid glands from 5/6 NX rats fed either a low (0.2%) or a high (1.2%) P diet, and receiving vehicle or Erlotinib (6 mg/kg body weight), daily, for 1 week.

Figure 3. Dietary P intake regulates parathyroid TACE translocation to the cell membrane

Representative immunostaining of TACE content at week 4, in parathyroid glands from 5/6 NX rats fed either a high P diet (0.9% P) for 4 weeks (HP), or for the first 2 weeks followed by a switch to a low P diet (0.2%) for 2 additional weeks (LP). The inserts show the higher TACE localization at the cell membrane in the HP group.

Figure 4. 1,25(OH)₂D synergizes with Erlotinib in moderating the increases in parathyroid TACE content in rat SH

Representative immuno staining for parathyroid TACE in glands from 5/6 NX rats fed high P diet and receiving either vehicle or 1,25(OH)₂D (1,25D; 4 ng every other day), Erlotinib (6 mg/kg body weight) and combined Erlotinib+1,25D treatment.

Figure 5. Increases in renal TACE and not hypertension mediate AngII-driven renal lesions in CKD

Ang II binding to its AT1 receptor induces increases in cytosolic TACE, and its translocation to the plasma membrane. TACE releases TGFα from its trans-membrane precursor, which then binds and activates the EGFR causing proteinuria, tubular hyperplasia, fibrosis, mononuclear cell infiltration. TGFα/EGFR-driven VDR reduction impairs 1,25(OH)₂D (1,25D)/VDR- renoprotection.

Figure 6. Increases in renal TACE correlate inversely with VDR content
Representative immunostaining for renal TACE (top panel) and VDR (lower panel) in kidneys from 5/6NX rats

Figure 7. Early correction of vitamin D deficiency moderates the increases in renal and macrophage TACE

Representative immunostaining for TACE content in kidney sections (top panel) and macrophage derived from bone marrow precursors (bottom panel) from 5/6NX rats fed a high P diet (HP) that were treated for 3 weeks, starting one week after the induction of renal damage, with vehicle, 25-hydroxy vitamin D (25D, once weekly to raise 25D up to 80 ng/ml); paricalcitol (P, 16 ng thrice weekly, a dose insufficient to suppress PTH), or the combination.